Pages that link to "Item:Q3576931"

The following pages link to Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931):

Displaying 20 items.

• Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
• Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data (Q2359487) (← links)
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes (Q2861956) (← links)
• Optimizing the concentration and bolus of a drug delivered by continuous infusion (Q2893431) (← links)
• A utility approach to individualized optimal dose selection using biomarkers (Q3299111) (← links)
• A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685) (← links)
• A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups (Q4628384) (← links)
• Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies (Q4690922) (← links)
• Rejoinder (Q4916484) (← links)
• Simple benchmark for complex dose finding studies (Q5170208) (← links)
• Biomarker-based precision dose finding for immunotherapy combined with radiotherapy (Q6572286) (← links)
• A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
• A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
• uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials (Q6627822) (← links)
• A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
• Utility based approach in individualized optimal dose selection using machine learning methods (Q6628609) (← links)
• Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies (Q6629385) (← links)